Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
224 USD -0.70% Intraday chart for Biogen Inc. -3.32% -13.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
REGENXBIO Inc. Announces Chief Executive Officer Changes CI
Biogen executive plays down looming competition for its Alzheimer's drug RE
BIOGEN EXEC SAYS THE ALZHEIMER'S DRUG MARKET "WILL DEVELOP FASTE… RE
Transcript : Biogen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM
Japan's Nikkei gains on chip shares boost; Fed policy in focus RE
FDA advisory panel votes in favor of data for Lilly Alzheimer's drug RE
US FDA advisers to review Eli Lilly Alzheimer's drug RE
Biogen, Eisai Say Alzheimer's Maintenance Treatment Application Accepted by US FDA MT
Fda Accepts Eisai's Filing of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease CI
US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug RE
Wedbush Adjusts Price Target on Biogen to $215 From $219 MT
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe DJ
Novartis and others face Italy antitrust probe over eye drug RE
Transcript : Biogen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 12:30 PM
Biogen: Brussels grants marketing authorization for Charcot disease CF
Disaster averted Our Logo
European Commission grants marketing approval to Biogen's ALS drug RE
Biogen Gets European Commission Approval for Qalsody MT
US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns MT
Sector Update: Health Care Stocks Slightly Higher Late Afternoon MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
Sector Update: Health Care MT
Biogen Agrees to Buy Human Immunology Biosciences For up to $1.8 Billion MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American MT
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating MT
Chart Biogen Inc.
More charts
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
225.6 USD
Average target price
284.6 USD
Spread / Average Target
+26.18%
Consensus
  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. News Biogen Inc.
  5. Sector Update: Health Care Stocks Slightly Higher Late Afternoon